Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2135451 | 1.00 | PDE4A (0.55) | PDE4ALMNATDP1USP2SLCO1B1 | |
| SCHEMBL29563836 | 0.92 | PDE4A (0.59) | PDE4ALMNATDP1USP2SLCO1B1 | |
| SCHEMBL19952979 | 0.92 | PDE4A (0.59) | PDE4ALMNATDP1USP2SLCO1B1 | |
| SCHEMBL3067831 | 0.92 | PDE4A (0.59) | PDE4ALMNATDP1USP2SLCO1B1 | |
| SCHEMBL258100 | 0.92 | PDE4A (0.59) | PDE4ALMNATDP1USP2SLCO1B1 | |
| SCHEMBL19952978 | 0.92 | PDE4A (0.59) | PDE4ALMNATDP1USP2SLCO1B1 | |
| SCHEMBL288150 | 0.92 | PDE4A (0.59) | PDE4ALMNATDP1USP2SLCO1B1 | |
| SCHEMBL8769028 | 0.87 | PDE4A (0.43) | PDE4ALMNATDP1USP2SLCO1B1 | |
| SCHEMBL9698714 | 0.80 | PDE4A (0.59) | PDE4ALMNATDP1USP2SLCO1B1 | |
| SCHEMBL5670801 | 0.78 | PDE4A (0.83) | PDE4ALMNATDP1USP2SLCO1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200046831-A1 | NANOEMULSION COMPRISING IMIDAZOQUINOLINE-BASED MATERIAL AND USE THEREOF | DANDI BIOSCIENCE INC. (KR) | 2020-02-13 | — | — | US | claimed |
| US-9205108-B2 | Treatment of traumatic brain injury by using gallium compounds to reduce oxidative stress levels | TROUP JAN M (US) | 2015-12-08 | — | — | US | claimed |
| US-20150306138-A1 | TREATMENT OF TRAUMATIC BRAIN INJURY BY USING GALLIUM COMPOUNDS TO REDUCE OXIDATIVE STRESS LEVELS | TROUP JAN M (US) | 2015-10-29 | — | — | US | claimed |
| US-20130045287-A1 | Treatment for Concussion using Gallium Compounds | TROUP JAN M (US) | 2013-02-21 | — | — | US | claimed |
| US-20200046831-A1 | NANOEMULSION COMPRISING IMIDAZOQUINOLINE-BASED MATERIAL AND USE THEREOF | DANDI BIOSCIENCE INC. (KR) | 2020-02-13 | — | — | US | disclosed |
| US-20190255100-A1 | TREATMENT OF CARDIOVASCULAR DISEASE BY USING GALLIUM COMPOUNDS TO BIND CALCIFIED LESIONS | LIPIDRISK, LLC | 2019-08-22 | — | — | US | disclosed |
| US-10259003-B2 | Omega-3 spray | THE PLANT BASED COMPANY (US) | 2019-04-16 | — | — | US | disclosed |
| US-20180093287-A1 | OMEGA-3 SPRAY | THE PLANT BASED COMPANY | 2018-04-05 | — | — | US | disclosed |
| EP-2341125-B1 | ENHANCED PRODUCTION OF LIPIDS CONTAINING POLYENOIC FATTY ACIDS BY HIGH DENSITY CULTURES OF EUKARYOTIC MICROBES IN FERMENTORS | DSM IP ASSETS BV (NL) | 2017-09-27 | — | — | EP | disclosed |
| EP-2338974-B1 | Enhanced production of lipids containing polyenoic fatty acids by high density cultures of microorganisms of the order Thraustochytriales in fermentors | DSM IP ASSETS BV (NL) | 2017-09-27 | — | — | EP | disclosed |
| US-20160106137-A1 | PROTEIN BEVERAGE AND METHOD OF MAKING THE SAME | NEXT PROTEINS INC (US) | 2016-04-21 | — | — | US | disclosed |
| US-9220292-B2 | Protein beverage and method of making same | NEXT PROBLEMS, INC. (US) | 2015-12-29 | — | — | US | disclosed |
| US-20070148305-A1 | PROTEIN BEVERAGE AND METHOD OF MAKING THE SAME | DAVINAS, LLC | 2007-06-28 | — | — | US | disclosed |
| US-7205018-B2 | Carbonated protein drink and method of making | NEXT PROTEINS, INC. (US) | 2007-04-17 | — | — | US | disclosed |
| WO-2007027213-A1 | HIGH ENERGY CARBONATED PROTEIN DRINK AND METHOD OF MAKING | NEXT PROTEINS, INC. (US) | 2007-03-08 | — | — | WO | disclosed |
| US-20060148757-A1 | Method of inhibiting formation of volatile aldehydes and/or decomposition of fatty acids and use thereof | Hayashibara Co., Ltd. (JP) | 2006-07-06 | — | — | US | disclosed |
| US-20060147602-A1 | High energy carbonated protein drink and method of making | NEXT PROTEINS, INC. | 2006-07-06 | — | — | US | disclosed |
| US-20060083844-A1 | Carbonated protein drink and method of making | DAVINAS, LLC | 2006-04-20 | — | — | US | disclosed |
| WO-2006042222-A2 | CARBONATED PROTEIN DRINK AND METHOD OF MAKING | NEXT PROTEINS, INC. (US) | 2006-04-20 | — | — | WO | disclosed |
| EP-1600496-A1 | METHOD OF INHIBITING FORMATION OF VOLATILE ALDEHYDES AND/OR DECOMPOSITION OF FATTY ACIDS AND USE THEREOF | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo (JP) | 2005-11-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130045287-A1 | Treatment for Concussion using Gallium Compounds | GRIK5, FABP7, GRM5 | PDE4A 1882/4885LMNA 4012/4885TDP1 2617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.